Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.

ABSTRACT: Patients with relapsed or refractory multiple myeloma (RRMM) have limited treatment options and poor survival outcomes. The increasing adoption of lenalidomide-based therapy for frontline treatment of multiple myeloma has resulted in a need for effective regimens for lenalidomide-refractory patients. This phase 1b study evaluated daratumumab plus carfilzomib and dexamethasone (D-Kd) in patients with RRMM after 1 to 3 prior lines of therapy, including bortezomib and an immunomodulatory drug; lenalidomide-refractory patients were eligible. Carfilzomib- and daratumumab-naïve patients (n = 85) received carfilzomib weekly on days 1, 8, and 15 of each 28-day cycle (20 mg/m² initial dose, escalated to 70 mg/m² thereafter) and dexamethasone (40 mg/wk). Of these, 10 patients r

SUBMITTER: Chari A 

PROVIDER: S-EPMC6676132 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature